Morgan Stanley Upgrades Merck to Overweight, Raises Price Target to $179
Nashnova编辑部
Morgan Stanley upgraded Merck (MRK) from Equal Weight to Overweight and lifted its price target from $116 to $179 — implying roughly 17% upside — betting that pipeline drugs can carry the company past the Keytruda patent cliff.
Why is Morgan Stanley upgrading now?
Analyst Terence Flynn sees three pipeline assets worth repricing: intismeran autogene and sac-TMT in oncology, plus tulisokibart for inflammatory bowel disease.
This means → Morgan Stanley isn't betting on Keytruda itself — it's betting that the next generation of drugs can pick up the revenue after Keytruda's exclusivity ends.
The target jumped from $116 to $179 in a single move — a 54%-plus raise, unusually large for a big-pharma stock.
How serious is the Keytruda patent cliff?
Keytruda is Merck's crown jewel — first-half sales already topped $16 billion, making it one of the world's best-selling immuno-oncology drugs.
Its key U.S. compound patent expires at the end of 2028, and the market has long worried that generics will flood in, sending revenue off a cliff.
In plain terms = one drug props up most of the company. If nothing replaces it when the patent expires, revenue drops like a cliff — hence "patent cliff."
How does Merck plan to fight back?
Flynn argues the patent expiry is not a major headwind. Merck's playbook: develop Keytruda combination formulations — pairing Keytruda with other drugs into new regimens — to extend the branded drug's lifecycle.
This means → even after Keytruda's original patent lapses, the combinations can qualify as "new drugs" with fresh patent protection, keeping generics at bay longer.
Meanwhile, if pipeline candidates reach the market on schedule, they open entirely new revenue streams beyond Keytruda.
How much room is left for the valuation to expand?
Flynn notes that as pipeline drugs clear clinical hurdles and new products launch, Merck's valuation multiple has room to rise further.
Merck shares are already up 45% year-to-date. Last Wednesday, a positive late-stage trial result — disclosed jointly with Moderna — sent the stock up 13% in a single session, its biggest one-day gain since March 13, 2009.
This reflects a shift in market sentiment from "wait and see" to "price it in" — positive pipeline news is now moving the stock directly.
What does the rest of Wall Street think?
Morgan Stanley's upgrade aligns with the broader consensus: of the 32 analysts covering Merck, 24 rate it Buy or Strong Buy.
The key test for this bullish view: whether pipeline drugs advance to commercialization on schedule.
In plain terms = Wall Street is nearly unanimous in its optimism, but that optimism rests on a single premise — new drugs making it to market. If trials stumble, the thesis reverses.
Content is for reference only, not financial advice.